Literature DB >> 19268270

Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease.

Valerio Nobili1, Naim Alkhouri, Anna Alisi, Simonetta Ottino, Rocio Lopez, Melania Manco, Ariel E Feldstein.   

Abstract

BACKGROUND & AIMS: Noninvasive methods are needed to identify pediatric nonalcoholic fatty liver disease (NAFLD), the most frequent chronic liver disease in children and adolescents in industrialized countries. Retinol-binding protein 4 (RBP4) is an adipocytokine that has been associated with the pathogenesis of insulin resistance. We tested the serum levels of RBP4 to assess their associations with the metabolic profile and histologic features in a large well-characterized group of children with NAFLD.
METHODS: The study included 59 children with biopsy-proven NAFLD. Histologic analyses were performed by an experienced hepatopathologist; the NAFLD activity score and fibrosis score were calculated for each patient. RBP4 levels in serum samples were measured by an enzyme-linked immunosorbent assay analysis. Anthropometric, blood pressure, and metabolic profile analyses (including glucose tolerance, fasting glucose, insulin, and lipid panel tests) were performed on samples from all patients.
RESULTS: Decreasing levels of RBP4 were associated significantly with increasing levels of serum triglyceride. High levels of RBP4 were associated significantly with low necroinflammatory activity, a low NAFLD activity score, and a low fibrosis score. Furthermore, serum RBP4 levels decreased significantly as disease severity increased; there was a stepwise decrease in RBP4 from children with steatosis (3.8 mg/dL) to borderline nonalcoholic steatohepatitis (2.9 mg/dL) to definitive nonalcoholic steatohepatitis (1.9 mg/dL) (P < .0001). This association remained significant after adjusting for other relevant clinical variables.
CONCLUSIONS: Our study shows an inverse relationship between RBP4 levels and degree of liver damage. RBP4 therefore might be a potential novel noninvasive marker of severity of pediatric NAFLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268270     DOI: 10.1016/j.cgh.2008.12.031

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  23 in total

1.  Comparative analysis of serum proteomes of moyamoya disease and normal controls.

Authors:  Eun-Jeong Koh; Han-Na Kim; Tian-Ze Ma; Ha-Young Choi; Yong-Geun Kwak
Journal:  J Korean Neurosurg Soc       Date:  2010-07-31

2.  Retinol binding protein 4 is associated with adiposity-related co-morbidity risk factors in children.

Authors:  Rushika Conroy; Yomery Espinal; Ilene Fennoy; Siham Accacha; Claudia Boucher-Berry; Dennis E Carey; Sharron Close; Deborah DeSantis; Rishi Gupta; Abeer A Hassoun; Loretta Iazzetti; Fabean J Jacques; Amy M Jean; Lesly Michel; Katherine Pavlovich; Robert Rapaports; Warren Rosenfeld; Elisabeth Shamoon; Steven Shelov; Phyllis W Speiser; Svetlana Ten; Michael Rosenbaum
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

Review 3.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design.

Authors:  Bryan Rudolph; Nicole Bjorklund; Nadia Ovchinsky; Debora Kogan-Liberman; Adriana Perez; Mark Liszewski; Terry L Levin; Michelle Ewart; Qiang Liu; Xiaonan Xue; Shankar Viswanathan; Howard D Strickler
Journal:  Contemp Clin Trials       Date:  2018-10-27       Impact factor: 2.226

5.  Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease.

Authors:  Lauren N Bell; Janice L Theodorakis; Raj Vuppalanchi; Romil Saxena; Kerry G Bemis; Mu Wang; Naga Chalasani
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

6.  Serum retinol binding protein 4 and clinical outcome in postoperative biliary atresia.

Authors:  Maneerat Chayanupatkul; Sittisak Honsawek; Voranush Chongsrisawat; Linda Vimolket; Yong Poovorawan
Journal:  Hepatol Int       Date:  2011-03-06       Impact factor: 6.047

Review 7.  NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?

Authors:  Shivaram P Singh; Rakesh K Barik
Journal:  J Clin Exp Hepatol       Date:  2019-09-21

8.  Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

Authors:  Hye Ran Yang; Hae Ryoung Kim; Myung Jin Kim; Jae Sung Ko; Jeong Kee Seo
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

Review 9.  Retinol and retinyl esters: biochemistry and physiology.

Authors:  Sheila M O'Byrne; William S Blaner
Journal:  J Lipid Res       Date:  2013-04-26       Impact factor: 5.922

10.  Retinol binding protein 4 and fatty liver: A direct link?

Authors:  Jacquelyn J Maher
Journal:  Hepatology       Date:  2013-08       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.